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Abstract: Peptide proﬁ  les generated using SELDI/MALDI time of ﬂ  ight mass spectrometry provide a promising source of 
patient-speciﬁ  c information with high potential impact on the early detection and classiﬁ  cation of cancer and other diseases. 
The new proﬁ  ling technology comes, however, with numerous challenges and concerns. Particularly important are concerns 
of reproducibility of classiﬁ  cation results and their signiﬁ  cance. In this work we describe a computational validation frame-
work, called PACE (Permutation-Achieved Classiﬁ  cation Error), that lets us assess, for a given classiﬁ  cation model, 
the signiﬁ  cance of the Achieved Classiﬁ  cation Error (ACE) on the proﬁ  le data. The framework compares the performance 
statistic of the classiﬁ  er on true data samples and checks if these are consistent with the behavior of the classiﬁ  er on the same 
data with randomly reassigned class labels. A statistically signiﬁ  cant ACE increases our belief that a discriminative signal 
was found in the data. The advantage of PACE analysis is that it can be easily combined with any classiﬁ  cation model and 
is relatively easy to interpret. PACE analysis does not protect researchers against confounding in the experimental design, 
or other sources of systematic or random error. We use PACE analysis to assess signiﬁ  cance of classiﬁ  cation results we have 
achieved on a number of published data sets. The results show that many of these datasets indeed possess a signal that leads 
to a statistically signiﬁ  cant ACE.
Keywords: ovarian cancer, pancreatic cancer, prostate cancer, biomarkers, bioinformatics, proteomics, disease prediction 
models, early detection
Introduction
High-throughput, low resolution time-of-ﬂ  ight mass spectrometry systems such as surface-enhanced 
laser desorption ionization - time of ﬂ  ight (SELDI-TOF) mass spectrometry (SELDI; Merchant and 
Weinberger, 2000; Issaq et al., 2002) and matrix-assisted laser desorption/ionization-time of ﬂ  ight mass 
spectrometry (MALDI) are just beginning to emerge as widely recognized high-throughput data sources 
for potential markers for the early detection of cancer (Wright et al., 1999; Adam et al., 2001; Petricoin 
et al., 2002). Spectra, or peptide proﬁ  les, are readily generated from easily collected samples such as 
serum, urine, lymph, and cell lysates. Comparisons have been made for a large number of cancers 
(Table 1) in search of diagnostic markers, with astonishingly good initial results for the classiﬁ  cation 
of cancer and control proﬁ  les collected within respective studies.
With these very promising results the questions related to the signiﬁ  cance and reproducibility of 
such classiﬁ  cation results become imminent. Reproducibility and signiﬁ  cance are essential with these 
types of data since the identity of the peptides located at clinically signiﬁ  cant m/z positions that translate 
to the classiﬁ  cation accuracy are unknown and their correctness cannot be veriﬁ  ed through independent 
experimental studies.
The process of peptide proﬁ  le generation is subject to many sources of systematic errors. If these 
are not properly understood they can potentially jeopardize the validity of the results. Such concerns 
have led to the analysis of possible biases present in published data sets and questions on the 54
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reproducibility of some of the obtained classiﬁ  cation 
results under the proper experimental setup 
(Baggerly et al., 2004). Such studies highlight the 
need for randomization of sample order acquisition 
and processing, maintaining constant protocols 
over the course of a study (including sample han-
dling and storage conditions), identiﬁ  cation of 
potential confounding factors and the use of a bal-
anced study design whenever possible to allow 
proper characterization of variation in the non-
diseased population. Certainly, a design matrix 
should be created for each study and inspected for 
patterns that reﬂ  ect complete or severe partial 
incidental confounding. In addition, multi-site 
validation studies, which are currently ongoing in 
the EDRN (Early Detection Research Network), 
can help to identify possible problems.
The peptide proﬁ  le data are not perfect and 
include many random components. The presence 
of large amounts of randomness is a threat for 
interpretive data analysis; the randomness increases 
the possibility of identifying a structure and pat-
terns in a completely uninformative signal. In such 
a case we want to have an additional assurance that 
the data and results of interpretive (classiﬁ  cation) 
analysis obtained for these data are not due to 
chance. Permutation tests (Kendall, 1945; Good, 
1994) used commonly in statistics offer one solu-
tion approach to this problem and allow us to 
determine the signiﬁ  cance of the result under ran-
dom permutation of target labels. In this work, 
building upon the permutation test theory, we 
propose a permutation-based framework called 
PACE (Permutation-Achieved Classiﬁ  cation Error) 
that can assess the signiﬁ  cance of the classiﬁ  cation 
error for a given classiﬁ  cation model with respect 
to the null hypothesis under which the error result 
is generated in response to random permutation of 
the class labels.
The main advantage of the PACE analysis is 
that it is independent of the model design. This 
allows the problems of choosing the best disease 
prediction model and achieving a signiﬁ  cant result 
to become decoupled. Many of the methods of 
high-throughput data analysis are very advanced, 
and thus may be poorly understood by the major-
ity of researchers who would like to adopt a reliable 
analysis strategy. Understanding PACE analysis 
involves only visual examination of an intuitive 
graph (e.g, Figure 1), which makes it easy to apply 
and explain to the novice.
In the following we ﬁ  rst describe the classiﬁ  cation 
problem and evaluation of the classiﬁ  cation per-
formance. Next we introduce the PACE framework 
that offers additional assessment of the signiﬁ  cance 
of the results. We compare PACE conceptually to 
existing conﬁ  dence assessment methods; it is found 
to be potentially complementary to conﬁ  dence 
interval-based bootstrap methods, which seek to 
determine whether a conﬁ  dence interval around a 
statistic of interest includes a single point (or a 
series of single points; i.e, the ROC curve). Finally, 
we apply PACE analysis to a number of published 
and new SELDI-TOF-MS data sets. We demon-
strate with positive and negative results the utility 
of reporting not only the ACE but also whether a 
given ACE is statistically signiﬁ  cant. PACE thus 
provides a beginning reference point for research-
ers to determine objectively whether they have 
constructed a signiﬁ  cant classiﬁ  er in the discovery 
phase.
Evaluation of classiﬁ  ers
Classiﬁ  cation
Classiﬁ  cation is the task of assigning class “labels” 
to sample data which come from more than 
Table 1: Published sensitivities and speciﬁ  cities of SELDI-TOF-MS proﬁ  ling for various types of cancers
Cancer Type SN, SP Reference
Ovarian Cancer 100%, 95% Petricoin et al., 2002
Prostate Cancer 100%, 100% Qu et al., 2002
Breast Cancer 90%, 93% Vlahou et al., 2003
Breast Cancer 91%, 93% Li et al., 2002
Head & Neck Cancer 83%, 90% Wadsworth et al., 2004
Lung Cancer 93.3%, 96.7% Xiao et al., 2003
Pancreatic Cancer 78%, 97% Koopmann et al., 200455
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one category. In our case, the classiﬁ  cation task 
is to determine whether a particular proteomic 
proﬁ  le comes from a case (cancerous) or control 
(non-cancerous) population. A classification 
model which assigns labels (either case or control) 
to proﬁ  les can be learned from training examples; 
proﬁ  les with known case and control labels. The 
goal is to achieve a classiﬁ  er that performs as best 
as possible on future data. Practical concerns 
related to the classiﬁ  er learning include the pos-
sibility of model overﬁ  t. The overﬁ  t occurs when 
the classiﬁ  cation model is biased strongly towards 
training examples and generalizes poorly to new 
(unseen) examples. Typically, model overfit 
occurs due to the inclusion of too many parameters 
in the model in conjunction with a small number 
of examples. To assess the ability of the classiﬁ  ca-
tion model to future data we can split the data 
from the study into training and test sets; the 
training set is used in the learning stage to build 
the classiﬁ  er, the testing set is withheld from the 
learning stage and it is used for evaluation pur-
poses only.
Evaluation
Training set: a collection of samples used to iden-
tify features and classiﬁ  cation rules based on dis-
criminatory information derived from the 
comparisons of features between or among 
groups.
Test set: a collection of samples to which the 
classiﬁ  cation rules learned from the training set 
are applied to produce an estimate of the exter-
nal generalizability of the estimated classiﬁ  ca-
tion error. The classiﬁ  cation error rate observed 
when classiﬁ  er is applied to them is called the 
test error rate. (Similarly, the sensitivity is called 
test set sensitivity, etc.). The classiﬁ  er rules 
learned include parameters optimized using the 
training set that are then included in the predic-
tion phase (for predictions on the test set). Test 
errors are usually higher than the training errors; 
Feng et al. refer to the difference as ‘optimism’; 
(Z. Feng, personal communication). Test errors 
are less biased than training errors, and therefore 
are more (but not completely) reﬂ  ective of the 
expected classiﬁ  cation error should the classiﬁ  er 
be applied to new cases from the same popula-
tion. The use of the test data set errors as the 
estimate is appropriate because it is low-biased 
compared to the classiﬁ  cation errors achieved 
using only the training data set. The test set may 
be a held-out set of samples, or, more commonly, 
a number of held-out sets to avoid inaccuracy 
of ACE.
Validation set: a set of samples collected and/or 
processed and/or analyzed in a laboratory or at a 
site different from the laboratory or site where the 
original training sets were produced. Validation 
sets are never included in the learning step. All 
validation sets are test sets but not all test sets are 
validation sets. The more independence there is 
among sample sets, laboratory protocols, and 
implementation of a particular method of predict-
ing class membership, the more robust the bio-
markers.
Cross-validation
Methods for estimating the test error include 
leave-one-out cross-validation, k-fold validation, 
and random subsampling validation. The selection 
of each of these depends in part on the number of 
samples available; these methods and their suit-
ability for application to the analysis of high-
throughput genomic and proteomic data sets 
have recently been explored (Braga-Neto & 
Dougherty, 2004). Use of the test error rates and 
performance measures derived from those rates 
allows one to assess the expected sensitivity (SN) 
and speciﬁ  city (SP) of a given test or classiﬁ  er; 
these performance measures are usually summa-
rized in a confusion matrix. Even with these esti-
mated performance measures, however, a more 
general question remains: for a broad range of 
potential outcomes and focus, from biomarker 
evaluation, discovery, validation and translation, 
what level of sensitivity is to be deemed signiﬁ  cant, 
or sufﬁ  cient, at a speciﬁ  ed level of speciﬁ  city? The 
clear overall objective of maximizing both SN and 
SP is built into the receiver-operator-characteristic 
(ROC) evaluation of a test, and the search of the 
most informative test usually seeks to maximize 
the area under the curve (AUC). Estimates of 
SN, SP, the ROC curve, and its area can all be 
determined using random subsampling validation. 
These approaches are well-studied, and their esti-
mates of expected classiﬁ  cation error are generally 
understood to be less biased than those estimated 
using training data sets.56
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Permutation–based validation
The individual performance statistics by themselves, 
do not always allow us to judge the importance of 
the result. In particular, one should be always 
concerned by the possibility that the observed 
statistic is the result of chance. Careful elimination 
of this possibility gives more credibility to the 
result and establishes its potential importance. 
Permutation test methods offer a class of tech-
niques that make this assessment possible under a 
wide variety of assumptions. Expected perfor-
mance under the null model varies with the 
speciﬁ  cs of a design, and the distribution of the 
performance statistics vary with the distribution 
of information among markers and the type of 
disease prediction model used.
Permutation test methods work by comparing 
the statistic of interest with the distribution of the 
statistic obtained under the null (random) condition. 
Our priority in predictive models is to critically 
evaluate the observed discriminatory performance. 
In terms of hypothesis testing the null hypothesis 
we want to reject is:
The performance statistic of the disease predic-
tion model on the true data is consistent with the 
performance of the model on the data with ran-
domly assigned class labels.
The objective of optimizing a classiﬁ  cation 
score itself is largely uncontrolled in most 
genomic and proteomic high-throughput analysis 
studies. Researchers do not, for example, typically 
attempt to determine and therefore do not report 
the statistical signiﬁ  cance of the sensitivity of a 
test, in spite of the existence of a number of 
approaches for performing such assessments. 
Here we introduce a permutation method for 
assessing signiﬁ  cance on the achieved classiﬁ  ca-
tion error (ACE) of a constructed prediction 
model.
Theory
A permutation test is a non-parametric approach 
to hypothesis testing, which is useful when the 
distribution for the statistic of interest T is 
unknown. By evaluating a classiﬁ  er’s statistic of 
interest when presented with data having randomly 
permuted labels, an empirical distribution over T 
can be estimated. By calculating the p-value of the 
statistic’s value when the classiﬁ  er is presented with 
the true data, we can determine if the classiﬁ  er’s 
behavior is statistically signiﬁ  cant with respect to 
the level of conﬁ  dence α.
Let
∏ d
be a set of all permutations of labels of the 
dataset with d examples. The permutation test 
(Mukherjee et al., 2003) is then deﬁ  ned as:
 •    Repeat  N times (where n is an index from 
1, ..., N)
   •   Choose a permutation
π 
n
  from a uniform distribution over
∏ d
   •     Compute the statistic of interest for 
this permutation of labels
  tT y y
n
x d x n
d
n = ( , ,..., , ) xx 1
1  
where
  xy i
i
n ,
π  
 denotes a proﬁ  le-label pair, where the 
proﬁ  le
  xi  
 is assigned the label according to the 
permutation
  πi
n  
 •    Construct an empirical cumulative distribu-
tion over the statistic of interest:
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  where H denotes the Heaviside function.
 •     Compute the statistic of interest for the 
actual labels,
  tT y y dd 01 1 = ( , ,..., , ) xx  
and its corresponding p-value57
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  00 ˆ() PP Tt =≤  
under the empirical distribution
  ˆ . P  
• If
  p0 ≤α  
reject the null hypothesis.
For our purposes, the statistic of interest T is 
the achieved classiﬁ  cation error (ACE).
Application of permutation-based 
validation to peptide proﬁ  ling (PACE)
We deﬁ  ne a classiﬁ  cation method f as all steps 
applied by a researcher to the data prior to some 
biological interpretation. These include the steps 
summarized in Table 2. In the case of SELDI/
MALDITOF-MS, this may include mass calibra-
tion, baseline correction ﬁ  ltering, normalization, 
peak-selection, a variety feature selection and clas-
siﬁ  cation, approaches. We take the position that 
every researcher that has decided to approach the 
problem of analysis of a high-throughput pro-
teomic data set has embarked on a journey of 
method development; i.e, the series of decisions 
made by the research itself is method f.
We assume that the researcher has adopted a 
study design that employs one or more training/test 
set splits, For our purposes, we use 40 random 
training/test splits to achieve a reasonably accurate 
estimate of ACE. A third validation sample can be 
set aside to verify the statistic on the pristine data. 
The validation set can either be produced at the 
same time, under the same conditions as the 
Table 2: Steps in the Analysis of High-Throughput Peptide Proﬁ  ling Spectra. These steps were elucidated in part in discussion with the 
EDRN Bioinformatics Working Group. We gratefully acknowledge their input.
Experimental Design Selection of type and numbers of samples to compare
Measurement Determination of sample rate 
Mass calibration
Preprocessing Proﬁ  le QA/QC ﬁ  ltering 
Variance correction/regularization 
Smoothing 
Baseline correction
Normalization (internal or external)
Data Representation Determination of proﬁ  le attributes:
  • Peak  selection
  • Whole-proﬁ  le
  • Partial-proﬁ  le
  • Binning
May also include peak-ﬁ  nding algorithms and peak-matching routines
Feature Selection Identiﬁ  cation of proﬁ  le features which are likely to be clinically 
signiﬁ  cant:
  •  Univariate statistical analysis
  •  Multivariate feature selection
Classiﬁ  cation Rendering sample class inferences
Computational Validation / Study 
Design
Calculation of an estimated classiﬁ  cation error rate which is hopefully unbiased and 
accurate. May involve:
  • Random  subsampling
  • Bootstrapping
  •  k-fold validation
  • Leave-one-out  validation
Signiﬁ  cance Testing of ACE PACE (this paper) 
Boostrap conﬁ  dence interval estimation (Efron and Tibshirani, 1997)58
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training/test data set. A more general estimate of 
the external validity of the estimate of the gener-
alization error and its robustness to different labo-
ratory conditions (and thus an assessment of the 
potential for practical (clinical) application) is 
obtained when the validation set is obtained at a 
different time or better yet in a different laboratory 
(as in multisite validation studies).
Permutation-Achieved Classiﬁ  cation 
Error (PACE) Analysis
Given the achieved classiﬁ  cation error (ACE) 
estimated via method f, generate an arbitrarily large 
number of new data sets with random sample rela-
beling. Method f is applied to each of the permuted 
data sets, resulting in a null distribution of ACE 
(called PACE). Lower 95th and 99th percentiles 
are located in PACE: ACE is then compared to 
these percentiles to assess the statistical signiﬁ  -
cance of the classiﬁ  er method f.
Alternatives to PACE
The permutation-based approach compares the 
error achieved on the true data to errors on 
randomly labeled data. It tries to show that the 
result for the true data is different from results on 
the random data, and thus it is unlikely the conse-
quence of a random process. We note that the 
permutation-based method is different and thus 
complementary to standard hypothesis testing 
methods that try to determine conﬁ  dence intervals 
on estimates of the target statistics. We also note 
that one may apply standard hypothesis testing 
methods to check if the target statistic for our clas-
siﬁ  cation model is statistically signiﬁ  cantly differ-
ent from either the fully random, trivial or any other 
classiﬁ  cation model. However, the permutation 
framework always looks at the combination of the 
data label generation and classiﬁ  cation processes 
and thus establishes the difference in between the 
performance on the true and random data.
Classiﬁ  cation error is a composite evaluation 
metric. Other types of performance measures for 
which conﬁ  dence intervals have been studied so 
far include signiﬁ  cance of SN at a ﬁ  xed SP (Linnet, 
1987), AUC (as implemented, for example, in 
Accu-ROC; Vida, 1993), and the ROC curve itself 
(Macskassy et al., 2003). Here we brieﬂ  y explain 
these options. Which performance measure 
to assess may vary according to strategy. Bootstrap-
estimated or analytically determined conﬁ  dence 
intervals around SN at a speciﬁ  ed SP (Linnet, 1987) 
requires that a desired SP be known, and this 
depends on its intent; for example a screening test 
should have very high SP to avoid resulting in too 
many false positives when applied to a population. 
Even here, however, “very high” and “too many” 
are rather context-dependent, should not be con-
sidered in a silo by ignoring existing or other 
proposed diagnostic tests. Acceptable FP values 
depend to a degree on the SP of existing practices, 
and to an extent on the prevalence of the disease. 
Any screen can be considered to change the 
prevalence of disease in the ‘potential patient’ 
population, and therefore follow-up with panels of 
minimally invasive markers, or multivariate studies 
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Figure 1: Example of PACE analysis. The 
permutation-achieved classiﬁ  cation error (PACE) 
distribution is estimated by computing a statistic 
(in this case, testing error) over repeated relabe-
ling of the sample data. The top solid line indicates 
the mean achieved classiﬁ  cation error (MACE) of 
this distribution. The low 95
th and 99
th percentiles 
of the PACE distribution are given by the dashed 
and dotted lines, respectively. If the achieved 
classiﬁ  cation error (ACE, bottom marked line) falls 
below a percentile band, it is a statistically sig-
niﬁ  cant result at that conﬁ  dence level. In this 
example, ACE for a Naïve Bayes classiﬁ  er using 
a weighted separability without peak selection or 
de-correlation (see below for details) falls consist-
ently below the 99
th percentile band of the PACE 
distribution. It can be said that this classiﬁ  er 
produced a statistically signiﬁ  cant result at the 
99% level.59
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of numerous risk factors (demographic, familial, 
vaccination, smoking history), and long-term 
monitoring, might make such screening worth-
while. High-throughput proteomics highlights the 
need for dynamic clinical diagnostics.
The various approaches suggested by Linnet 
were extended and revised with a suggestion by 
Platt et al. (2000) to adopt the bootstrap conﬁ  dence 
interval method (Efron and Tibshirani, 1993). 
A working paper by Zhou and Qin (2003) explores 
related approaches. One strategy is to perform 
bootstrapping (Efron and Tibshirani, 1993) and 
calculate a 1-α conﬁ  dence interval around a mea-
sure of interest. Bootstrapping is a subsampling 
scheme in which N data sets are created by sub-
sampling the features of the original data set, with 
replacement. Each of the N data sets is analyzed. 
Confidence intervals around some measure of 
interest (T) can be calculated or consensus informa-
tion can be gathered; in either case, variability in 
an estimate T is used a measure of robustness of T. 
Various implementations of the bootstrap are avail-
able; the least biased appears to be bias-corrected 
accelerated version (Efron and Tibshirani, 1993).
A second strategy is to calculate confidence 
intervals around the AUC measure. Bootstrapping 
(Efron and Tibshirani, 1997) is sometimes used to 
estimate AUC conﬁ  dence intervals. Relying on 
conﬁ  dence in the AUC can be problematic because 
it reports on the entire ROC, and, in practice, only 
part of the ROC is considered relevant for a par-
ticular application (e.g, high SP required by screen-
ing tests. A literature on assessing the signiﬁ  cance 
of partial ROC curves has been developed (Dodd 
and Pepe, 2003; Gefen et al., 2003); a recent study 
(Stephan, Wesseling et al., 2003) compared the 
features and performance of eight programs for ROC 
analysis.
A third strategy is to calculate bootstrap conﬁ  -
dence bands around the ROC curve itself (Macskassy 
et al., 2003). Under this approach, boot  strapping is 
explored and bands are created using any of a variety 
of ‘sweeping’ methods that explore the ROC curve 
in one (SN) or two (SN and 1-SP) dimensions.
Experimental results of PACE 
analysis on clinical data
We applied PACE analysis to the following 
published data sets, and one new data set from 
the UPCI, using a number of methods of 
analysis:
  •  UPCI Pancreatic Cancer Data
  •    Ovarian Cancer Data (D1; Petricoin et al., 
2002)
  •    Ovarian Cancer Data (D2; Petricoin et al., 
2002)
  •  Prostate Cancer Data (Qu et al., 2002)
The UPCI’s pancreatic cancer data are only 
in the preliminary stages of analysis and we 
report only initial results. An ongoing study 
with an independent validation set is underway. 
Preoperative serum samples were taken from 
32 pancreatic cancer cases (17 female, 15 male). 
Twenty-three non-cancer age, gender, and smok-
ing history-matched controls were analyzed; 
ages ranged from 34 to 87, pancreatic cancer 
cases had a mean age of 64, controls had a 
mean age of 67 (p=0.19). Of the cancer sam-
ples, 16 were resected; 6 patients had locally 
advanced unresectable disease, and 10 had meta-
static disease.
The ovarian cancer datasets D1 and D2 
(Petricoin et al., 2002) were obtained through the 
clinical proteomics program databank (http://
ncifdaproteomics.com/). Both datasets were cre-
ated from the same samples, but D2 was processed 
using a different chip surface (WCX2) as opposed 
to the hydrophobic H4 chip used to generate the 
data in D1. The samples consist of 100 controls: 
61 samples without ovarian cysts, 30 samples 
with benign cysts smaller than 2.5 cm, 8 samples 
with benign cysts larger than 2.5 cm, and 1 sam-
ple with benign gynecological disease. The samples 
include 100 cases: 24 samples with stage I ovarian 
cancer, and 76 samples with stage II, II and IV 
ovarian cancer.
The prostate cancer dataset (Qu et al., 2002) 
was also acquired from the clinical proteomics 
program databank. It consists of 253 controls: 
75 samples with a prostate-speciﬁ  c antigen (PSA) 
level less than 4 ng/ML, 137 samples with a PSA 
level between 4 and 10 ng/ML, 16 samples with a 
PSA level greater than 10 ng/ML, and 25 samples 
with no evidence of disease and PSA level less than 
1 ng/ML. 69 cases exist in this dataset: 7 samples 
with stage I prostate cancer, 31 samples with 
stage II and III prostate cancer, and 31 samples 
with biopsy-proven prostate cancer and PSA level 
greater than 4 ng/ML.60
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Methods Applied and Evaluated
Table 3 gives a summary of methods applied in the 
analysis. A brief description of some of these 
methods is provided below. A thorough description 
of these methods can be found in Hauskrecht et al. 
(2005, in press).
Peak detection
In some circles it is a strong belief that only peaks 
in a proﬁ  le represent informative features of a 
proﬁ  le. Peak detection can take place before per-
forming further feature selection in order to limit 
the initial amount of the proﬁ  le to be considered. 
There are various ways in which peak detection 
can be performed; for the purposes of our experi-
ments, we utilize a peak detection method that 
examines the mean proﬁ  le generated for all training 
samples, and then determines its local maxima. 
The local maxima positions become the only fea-
tures considered for feature selection later in the 
pipeline displayed in Table 3. Alternatively, we can 
ignore the peak detection phase completely and 
consider the entire proﬁ  le for feature selection.
Feature selection methods
Fisher Score: The Fisher score is intended to be 
a measure of the difference between distributions 
of a single variable. A particular feature’s Fisher 
score is computed by the following formula:
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  μi
± 
is the mean value for the i
th feature in the positive 
or negative proﬁ  les, and
  σi
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is the standard deviation. We utilize a variant of 
this criterion (Furey, 2000), computed with the 
following formula:
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To avoid confusion, we refer to the second 
formula above as our “Fisher-like score”. Features 
with high Fisher scores possess the desirable qual-
ity of having a large difference between means of 
case versus control groups, while maintaining low 
overall variability. These features are more likely 
to be consistently expressed differently between 
case and control samples, and therefore indicate 
good candidates for feature selection.
AUC Score (for feature selection): Receiver 
operating characteristic curves are commonly used 
to measure the performance of diagnostic systems 
in terms of their “hit-or-miss” behavior. By com-
puting the ROC curve for each feature individually, 
one can determine the ability of that feature to 
separate samples into the correct groups. Measur-
ing the area under the ROC curve (Hanley et al., 
1982) then gives an indication of the feature’s 
probability of being a successful biomarker. The 
AUC score for a given feature is then obtained by 
integrating over the ROC curve for that feature. As 
with the Fisher score, higher AUC scores signify 
better feature candidates.
Univariate t-test: The t-test (Baldi et al., 2001) 
can be used to determine if the case versus control 
distributions of a feature differ substantially within 
the training set population. The t statistic, repre-
senting a normalized distance measurement 
between populations, is given as
Table 3: List of methods applied to datasets. Each dataset was 
evaluated using PACE analysis with every possible combination of 
these methods. MAC = maximum allowed correlation.
Method Options (Choice of one)
Peak Detection   •   On (Select only peaks)
  •   Off (Use the whole proﬁ  le)
Feature Selection   •   Area under ROC curve 
(AUC)
  • Fisher  score
  • J5  test
  •   Simple separability criterion
  • t-test  score
  •   Weighted separability 
criterion
De-correlation Enhance-
ment
  • On  (MAC   1)
  • Off  (MAC  = 1)
Classiﬁ  cation Model   •   Naïve Bayesian Classiﬁ  er
  •   Support Vector Machine 
(SVM)61
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where
  μσ −− ,  
are the empirical mean and standard deviation for 
the i
th feature in the
n−
control samples, and
  μσ ++ ,  
are likewise the empirical mean and standard 
deviation for the i
th feature in the case samples. 
The t statistic follows a Student distribution with
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degrees of freedom. For each feature, one can then 
calculate the t statistic and associated f, and deter-
mine the associated p-value with a predetermined 
conﬁ  dence level from a standard table of signiﬁ  -
cance. Smaller p-values indicate it is unlikely the 
observed case and control populations of the i
th 
feature are similar by chance. Thus, it is likely that 
the i
th feature is represented in a way that is statisti-
cally signiﬁ  cant between case and control examples, 
making it a good candidate for feature selection.
We also evaluated feature selection using simple 
separability, weighted separability, and the J5 test 
(Patel and Lyons-Weiler, 2004).
De-correlation enhancement: After differential 
feature selection, we can perform further feature 
evaluation to avoid highly correlated features. These 
may be of interest for interpreting the biological 
sources of variation among peptides (such as carrier 
proteins; Mehta et al., 2003). For the purpose of 
constructing independent classiﬁ  ers, however, it 
may be better to avoid using non-independent 
features - if only to increase the number of features 
included after feature selection - but also to avoid 
overtraining on a large number of highly correlated 
features. One way to avoid these correlated features 
is de-correlation (removal of features which are 
inter-correlated beyond some pre-determined 
threshold). All of the methods described so far can 
be evaluated with and without de-correlation.
Principal component analysis: Principal com-
ponent analysis, a type of feature construction, 
incorporates aspects of de-correlation by grouping 
correlated features into aggregate features (com-
ponents), which are presumed to be orthogonal (i.e, 
uncorrelated).
Classiﬁ  cation models
Naïve Bayes: The Naïve Bayes classiﬁ  er makes 
the assumption that the state of a feature (indicating 
membership in the case or control group) is 
independent of the states of other features when 
the sample’s class (case or control) is known. Let
  Xx x x n ={ , ,..., } 12  
be a sample consisting of n features, and
  Cc c c m ={ , ,..., } 12  
be a set of m target classes to which X might belong. 
One can compute the probability of a sample belong-
ing to a particular class using Bayes’ rule:
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The likelihood of sample X belonging to a par-
ticular target class cj is given as the product of each 
probability density function for each feature in the 
population of cj.
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For our purposes, we assume each feature xk 
follows a Gaussian distribution, although other 
distributions are possible. Thus, the probability 
density function for feature xk is
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are the mean and standard deviation of the k
th 
feature within the population of samples belong-
ing to class cj. These two values, and their cor-
responding pair for the control population, must 
be estimated using the empirical information 
seen in the training set for each feature. The 
estimates are then used in the computation 
above during the predictive process on the test-
ing set.
Support Vector Machine (SVM): One might 
imagine a sample with n features as a point in an 
n-dimensional space. Ideally, we would like to 
separate the n-dimensional space into partitions 
that contain all samples from either case or 
control populations exclusively. The linear support 
vector machine or SVM (Vapnik 1995, Burges 
1995) accomplishes this goal by separating the 
n-dimensional space into 2 partitions with a hyper-
plane with the equation
  w+
T Xw 0 0 =  
where w is the normal to the hyperplane, and
w0
is the distance between the “support vectors”. 
These support vectors are the representative 
samples from each class which are most helpful 
for deﬁ  ning the decision boundary. The parameters 
of the model, w and
w0
can be learned from data in the training set 
through quadratic optimization using a set of 
Lagrange parameters
  ˆi α  
(Scholkopf 2002). These parameters allow us 
to redeﬁ  ne the decision boundary as
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where only samples in the support vector con-
tribute to the computation of the decision boundary. 
Finally, the support vector machine determines a 
classiﬁ  cation
 
ˆi y
 
for the i
th sample as seen here:
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where negative
  ˆi ys  
will occur below the hyperplane, and positive
  ˆi ys  
will occur above it. Ideally, all samples from 
one group will have negative
  ˆ y  
while all others will have positive
  ˆi y  
PACE Results
All four cancer datasets were analyzed using 
classifiers defined by differing configurations 
of feature selection criteria, peak selection, de-
correlation, and classiﬁ  cation models. De-correlation 
MAC thresholds range from 1 (no de-correlation) 
to 0.4 (strict de-correlation) in increments of 0.2. 
To assess the statistical signiﬁ  cance of the classi-
ﬁ  ers generated through these conﬁ  gurations, PACE 
analysis was performed using 100 random permu-
tations of the data over 40 splits into training 
and testing sets. Classiﬁ  ers were evaluated over 
the range of 5 to 25 features, in increments of 
5 features.
For illustrative purposes, examples of PACE 
graphs are presented in the appendices of this work. 
These graphs represent only a portion of the clas-
siﬁ  ers evaluated for this work. In particular, the 
appendices present PACE graphs for SVM classi-
ﬁ  ers enforcing a 0.6 MAC threshold, both before 
and after peak selection, for each of the univariate 
feature selection methods.
UPCI Pancreatic Cancer Data
Each possible configuration of classification 
models produced a statistically signiﬁ  cant classiﬁ  er 63
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at the 99% level. This trend was observed for all 
feature sizes in each classiﬁ  er. See ﬁ  gures A.1 
through A.6 for examples of PACE analysis on this 
dataset using different feature selection criteria.
Ovarian Cancer Data (D1; Petricoin 
et al., 2002)
Each possible configuration of classification 
models produced a statistically signiﬁ  cant classiﬁ  er 
at the 99% level. This trend was observed for all 
feature sizes in each classiﬁ  er. See ﬁ  gures B.1 
through B.6 for examples of PACE analysis on this 
dataset using different feature selection criteria.
Ovarian Cancer Data (D2; Petricoin 
et al., 2002)
Each possible conﬁ  guration of classiﬁ  cation mod-
els produced a statistically signiﬁ  cant classiﬁ  er at 
the 99% level. This trend was observed for all 
feature sizes in each classiﬁ  er.
See ﬁ  gures C.1 through C.6 for examples of 
PACE analysis on this dataset using different fea-
ture selection criteria.
Prostate Cancer Data (Qu et al., 2002)
Under random feature selection, several classiﬁ  ers 
were produced which were not statistically 
signiﬁ  cant at the 99% or 95% level. Using the 
Naïve Bayes classiﬁ  cation model, the gener-
ated classiﬁ  ers were not signiﬁ  cant at the 95% 
level for small amounts of features (5-15). As 
de-correlation becomes stricter, the classiﬁ  ers lost 
statistical signiﬁ  cance at high amounts of features 
where they had been signiﬁ  cant with a more 
lenient MAC. When coupling this technique with 
peak selection, no statistically signiﬁ  cant classi-
ﬁ  ers were produced. With an SVM-based classi-
ﬁ  er using random feature selection, the produced 
classiﬁ  ers were signiﬁ  cant at the 99% level except 
when using the initial 5 features. Changes in 
MAC and peak selection did not change this 
behavior.
In general, Naïve Bayesian classiﬁ  ers using 
univariate feature selection criteria are signiﬁ  cant 
at the 99% level as long as peak selection is not 
performed beforehand. The one exception was the 
J5 test, which was unable to produce a signiﬁ  cant 
classiﬁ  er at the 95% level without the aid of 
de-correlation. Applying de-correlation allowed 
these classiﬁ  ers to achieve signiﬁ  cance at the 99% 
level. When performing peak selection, only the 
classifiers produced using the strictest MAC 
thresholds (0.6, 0.4) were able to achieve some 
form of signiﬁ  cance, and even then, only at high 
amounts of features (15-25). The weighted sepa-
rability score was unable to produce a signiﬁ  cant 
naïve Bayes classiﬁ  er using peak selection.
SVM classiﬁ  ers using univariate feature selec-
tion criteria were nearly always signiﬁ  cant at the 
99% level, either with or without peak selection. 
The few instances where there was no signiﬁ  cance 
at the 95% level occurred using the J5 and simple 
separability scores without de-correlation. In the 
case of the J5 score, lowering the MAC to 0.8 
remedied the situation, while the simple separabil-
ity score improved simply through incorporating 
additional features.
See ﬁ  gures D.1 through D.6 for examples of 
PACE analysis on this dataset using different fea-
ture selection criteria.
Discussion
We have before us a daunting challenge of creating 
conduits of clear and meaningful communication 
and understanding between ‘consumers’ (statisti-
cians, computational machine learning experts, 
bioinformaticians) and the producers of high 
throughput data sets. The objective is to maximize 
the rate at which clinically signiﬁ  cant patterns can 
be discovered and validated. Disciplines can be 
bridged in part by a straightforward reference point 
on performance provided by decision-theoretic 
performance measures. Nevertheless, performance 
characteristics that are typically reported (SN, SP, 
PPV, NPV) only provide partial information on 
performance (the method’s performance in the 
alternative case). Researchers may be reluctant to 
publish results that have ‘relatively low’ SN and 
SP (e.g, 0.75, 0.8), and yet this level of perfor-
mance may in fact be highly surprising given the 
sample numbers and degree of variability (due to 
noise variance). Stellar results such as high 90’s 
sensitivity and speciﬁ  city predominate in the pub-
lished cancer literature (Table 1), posing the ques-
tion of whether the early reports of high performance 
may have set the standard too high. Some bio-
logical signal and powers of prognosis can be 64
Lyons-Weiler, Pelikan, and Zeh, et al
Cancer Informatics 2005:1
expected to be lower. Our work focuses on the 
question: what represents a remarkable SN? SP? 
AUC? ACE? We study this from the perspective 
that proteomic proﬁ  ling represents only one of 
many different sources of potential clinically sig-
niﬁ  cant information, and that combined use of 
panels of biomarkers and other molecular and 
classical diagnostic information is likely to be 
required if proteomic proﬁ  ling becomes widely 
adopted.
Minimize ACE: Conjecture or Tautology?
In microarray analysis, most papers describe a new 
algorithm or test for ﬁ  nding differentially expressed 
genes. This makes is difﬁ  cult to assess the validity 
of a given analytical strategy (method of analysis). 
We recommend that a standard be considered for 
the assessment of the impact of particular decisions 
in the construction of an analytical strategy, includ-
ing decisions made during pre-processing (Figs. 2 
and 3): Speciﬁ  cally,
Any method that results in a signiﬁ  cant ACE is 
to be preferred over methods that do not achieve 
signiﬁ  cance. All signiﬁ  cant methods (at a speciﬁ  ed 
degree of signiﬁ  cance) are equally justiﬁ  ed – for 
the time being.
It is possible that different methods that achieve 
signiﬁ  cant ACE will identify distinct feature sets, 
in which case each feature set is potentially inter-
esting.
Note that we are not suggesting that reproduc-
ibility is not important; i.e, ideally, the same meth-
ods on similarly-sized different data sets should 
achieve similar levels of signiﬁ  cance. Indeed, 
reproducibility is key; therefore, the methods that 
yield similar levels of signiﬁ  cance in repeated 
experiences are also validated.
Note also that we are also not recommending 
that one should adopt the somewhat opposing posi-
tion that
The method that minimizes ACE will tend to be 
most signiﬁ  cant, and therefore will likely be best 
justiﬁ  ed.
In contrast, we consider it likely that clinically 
signiﬁ  cant information may exist at a variety of 
scales within these large data sets. The search for 
a method-any method- with the most signiﬁ  cant 
ACE from a single data set seems likely to lead to 
overestimates of the expected clinical utility of a 
set of biomarkers. Comparisons of ACE across 
cancer types and with independent data set would 
be informative.
Nonsigniﬁ  cant Results
Reasons for negative results might include no 
biological signal, poor study design or laboratory 
SOPs, poor technology, or low biological signal 
(requiring larger numbers of samples). It is our 
position that researchers are better informed 
whether the result is signiﬁ  cant or not. For exam-
ple, a non-significant ACE may inform the 
researcher that they should reﬁ  ne or redirect their 
research question; an example might include early 
detection of a given disease providing a negative 
result in the pre-disease state, suggesting that one 
might move the focus to early stage disease instead 
of pre-disease. While the clinical prediction of a 
potential outcome during the course of disease may 
not be possible from the preconditioned state, the 
research might shift focus toward ‘how early can 
this condition be predicted?’ While we report few 
non-significant results, we have seen non-
signiﬁ  cant results from unpublished, proprietary 
studies of which we cannot report the details. The 
results are unpublished in part due to the negative 
results, and in part due to the changes in the 
experimental design that has resulted due to achiev-
ing a negative result.
Relation of PACE to Similar Methods
PACE creates a distribution of the expected ACE 
under the null condition. The ﬁ  xed measure ACE 
is the average classiﬁ  cation error over all random 
sub-samplings. This generates a distribution around 
ACE, and the determination of signiﬁ  cance could 
involve a comparison of the degree of overlap 
between the ACE and PACE distributions. As we 
have seen, PACE is similar in focus to a number 
of alternative methods with slightly distinct imple-
mentations and foci. These include the ROC boot-
strap confidence interval on AUC, confidence 
interval estimation around SN at a ﬁ  xed SP, and 
bootstrap bands around the ROC curve itself. The 
bootstrap ROC is used to determine a conﬁ  dence 
interval around an estimated area under the ROC 
curve (AUC); we are most interested in the speciﬁ  c 
part of feature space where a classiﬁ  er works best, 
not in the overall performance of a classiﬁ  er over 65
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a range of stringency, and thus PACE focuses on 
comparing a point estimate of statistic theta to its 
null distribution. A traditional limitation of permu-
tation tests is an assumption of symmetry; in our 
case, we are only interested in the lower tail of the 
PACE distribution. In the case of individual per-
formance measures (SN, SP) or the composite 
AUC, one would be interested only in the upper 
tail of ACE. Symmetry is also known to be an 
especially important assumption when estimating 
the conﬁ  dence interval around the AUC (Efron and 
Tibshirani, 1993).
The question of relative suitability of these 
alternatives should be determined empirically to 
determine if any practical differences exist in this 
particular application. So the question is posed: 
which statistical assessment of conﬁ  dence is of 
most practical (applied) interest: the speciﬁ  c mea-
surement of classiﬁ  cation error achieved by x in the 
learning stage of the actual study, or the distribution 
of the classiﬁ  cation error in imagined alternative 
cases? We prefer to make our inferences on the data 
set at hand, for the time being, using imagined 
alternatives that involve a (hopefully) well-posed 
null condition. The bias-corrected accelerated boot-
strap conﬁ  dence interval (Efron and Tibshirani, 
1993), which is range-respecting and range-
preserving (and unbiased, as the name suggests) 
corrects for differences between the median AUC 
of some of the pseudosamples and that of the 
original sample, making the imagined alternative 
samples more like the actual sample. This method 
should also be explored in this context.
Some of these disparate methods could also 
potentially be combined (e.g, PACE as the null 
distribution and ROC bootstrapping to assess con-
ﬁ  dence intervals around ACE). This would use the 
degree of overlap of distributions instead of spe-
ciﬁ  c instance outside of a generated distribution. 
A more formal exploration of these possibilities 
seems warranted.
Robustness of PACE and Permutation 
Approaches to the Stark Realities 
of High-Throughput Science
PACE provide a reference point that is robust to 
many of the vagaries in study design common to 
peptide proﬁ  ling studies, such as different numbers 
of technical replicates per sample that result 
from the application of QA/QC. Compared to 
distribution-dependent criteria that would otherwise 
require adjustments to degrees of freedom, both 
PACE and the bootstrap are relevant for the data 
set at hand.
Caveats
PACE and the other methods cited here do not 
protect incidental partial or complete confounding. 
True validation of the results of any high-throughput 
analysis should involve more than one site, ideally 
with the application of a speciﬁ  c classiﬁ  er rule 
learned at site A to data generated at site B. Further, 
to protect against ampliﬁ  cation of local biases by 
data preprocessing steps, the preprocessing must 
be wrapped within the permutation loop.
A Word on Coverage
It is important to consider in the development and 
evaluation of biomarker-based classiﬁ  cation rule 
whether a sample is classiﬁ  able; i.e, do the rules 
developed and data at hand provide sufﬁ  ciently 
precise information on a given sample. The propor-
tion of samples that are predictable in a data is 
defined as coverage. If a strategy is adopted 
whereby a number of samples are not classiﬁ  ed, 
the evaluation scheme (whether it be a bootstrap, 
random subsampling-derived conﬁ  dence boundar-
ies, or permutation signiﬁ  cance test) should also 
be forced to not classify the same number of 
samples. These ‘enforced passes’ on a sample must 
be checked and enforced after the prediction stage 
to conserve the numerical and statistical aspects of 
the study design and data set (e.g,s, number of 
samples; variability within m/z class).
Research is needed to determine the importance 
of asymptotic properties, dependencies of the 
bootstrap ROC on the monotonic or jaggedness 
of the ROC curve, and the use of combined distri-
butions (i.e, measure of degree of overlap between 
the PACE distribution, as the null distribution, and 
the bootstrap ROC curve as variability in the esti-
mated classiﬁ  er performance measure of interest 
in separate instance of the study).
Towards a More Complete Characterization 
of the Problem
In the consideration of further development and 
improvements in analytic methods for the analysis 66
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of peptide profiles, we assume that detailed 
descriptions of fundamental characteristics of low-
resolution peptide proﬁ  les can be used to help set 
priorities in the construction of particular strate-
gies. These descriptions/observations include
•  an acknowledgement of somewhat high mass 
accuracy (0.2-0.4%);
•  a comprehension that individual m/z values are 
not speciﬁ  c (i.e, they are not unique to indi-
vidual peptides), and therefore intensity mea-
sures at a given m/z value reﬂ  ect sum intensity 
of ‘peptide m/z classes’, which may or may not 
be functionally associated;
•  an understanding that peptides do not map to 
single individual peptides; i.e, they exist two or 
more times in the proﬁ  le at different m/z values 
as variously protonated forms. Each peptide 
may have a roughly unique signature, and pat-
tern matching forms the basis of peptide ﬁ  nger-
print data mining, but a peptide need not occur 
as a single peak;
•  an understanding that m/z variance will contain 
biological sources (mass shifts due to amino 
acid sequence variation and varying degrees of 
ubiquination and cleavage, binding of peptides 
with others), chemical, and physical components 
(mass drift), and thus models that allow the 
statistical accounting of each of these variance 
components are needed;
•  an understanding that high - intensity measure-
ment in SELDI-TOF-MS proﬁ  les tend to exhibit 
higher variance, which suggest that reliance of 
peaks for any inference (analyzing peaks only, 
aligning peaks, or normalizing proﬁ  les to peaks) 
may add large, unwanted components of vari-
ance or restrict ﬁ  nding to peptides with intensi-
ties that are most inaccurately measured;
•  the acknowledgment that the m/z vector is an 
arbitrary vector along which intensity values of 
similarly massed and charged peptides are 
arranged, and, as an arbitrary index in and of 
itself may require (or deserve) no profound 
biological explanation and may or may not offer 
a profound biological insight related to the 
clinical questions at hand beyond a guide to 
identity of peptide by pattern matching;
•  observations that features determined to be 
signiﬁ  cant tend to be locally correlated and 
that long-range correlations also exist, and that 
both artifactual and biologically important 
correlations and anti-correlations may exist at 
both distances;
•  an expectation that correlations may exist that 
reﬂ  ect protonated forms of peptides and that 
some correlation/anticorrelation pairs may 
reﬂ  ect real peptide biology, such as enzymatic 
cleavage cascades;
•  similarly, the observation that at least part of 
the local autocorrelation observed in the proﬁ  le 
is likely due to poor resolution (mass drift), and 
reflects a physical property of the profiles 
(instrument measurement error and resolving 
power). It may also reﬂ  ect smoothing due to 
natural biological variation in the population 
from which the samples were drawn, the effects 
of summing intensities of distinct peptides that 
share similar but not identical m/z values. One 
might consider whether the local correlations 
all reﬂ  ect real biological properties of single 
peptides at particular m/z positions, and, if not, 
they may offer no biological insight and may 
require no biological explanation (i.e, local 
autocorrelation may be simple artifact of degree 
of resolution of the instrument and the lack of 
speciﬁ  city of m/z values).
These descriptions may help motivate research 
on variance corrections, de-correlation, the use of 
PCA, proﬁ  le alignment strategies, and attempts at 
transformation.
Other Open Questions
As high-throughput genomic and proteomic data 
become less expensive, and the laboratory equip-
ment spreads into an increasing number of facili-
ties, it seems likely that different laboratories will 
study the sample problem with completely inde-
pendent effort. Published data sets, therefore, 
represent profoundly useful potential source of 
corroboration, or validation, of biomarker sets that 
might be expected to exhibit reproducible differ-
ences in large portions of the patient population. 
A careful characterization and validation of those 
differences, as a step that is independent of the 
question of potential clinical utility, is essential in 
these studies. True validation by planned repeated 
experiments may seem daunting, or unwarranted 
at this early stage, and the tendency will be to 
attempt to validate markers deemed to be signiﬁ  -
cant in a small study using other technology 67
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(immunohistochemistry, for example). In this case, 
absence of validation of speciﬁ  c proteins with other 
technology is not complete refutation due to the 
potential for idiosyncrasies in this new application 
of mass spec technology. Computational validation 
applied at the step of feature selection alone could 
prove invaluable (i.e, which features are reproduc-
ibly different between cases and controls, respond-
ers and nonresponders, in independently analyzed 
subsets or splits of the data samples?)
Large multi-year and multi-site studies
As unlikely as large-scale repeated studies may 
seem, it seems imminent that studies of peptide 
proﬁ  les from thousands of patients and normal 
donors will be forthcoming. What are the practical 
problems in such a setting? We would advocate 
avoiding the temptation to view one large data set 
(say, 5,000 patient, 5,000 normal) as a single study, 
and would recommend analysis of multiple, ran-
dom independent (non-overlapping) subsets, which 
would provide true validation of feature selection 
methods and classiﬁ  cation inferences. Such large 
studies will occur over long timer periods. Labora-
tory conditions change, and manufacturers change 
kits and protocols; thus, to maximize the general-
izability of the performance characteristics of a 
trained classiﬁ  er, training and test sets should be 
randomly selected and blinded. We must remember 
that learning is asymptotic. Therefore, researchers 
should avoid evaluating a classiﬁ  er built on train-
ing data set 1 produced at time 1 with testing set 
produced at time 2; instead, they should randomize 
the data over the entire time period, even if this 
means re-learning a classiﬁ  er after publishing an 
initially internally valid classiﬁ  er using data set 1. 
This approach still involves training, but protects 
against a biased (overly pessimistic) result due to 
shifts in laboratory conditions.
Future Directions in Peptide Proﬁ  ling
Given that the distribution of pure noise variance 
over the m/z range is not uniform under the null 
condition, univariate feature selection methods 
such as t-tests, Fisher’s score, area under the curve 
(AUC) and their nonparametric alternatives are 
perhaps best applied as permutation tests to attempt 
to equalize the Type 1 error rate over the m/z range 
included in an analysis. When combined with 
PACE, this greatly increases the computational 
burden of analyzing even a small set of proﬁ  les, 
but the pay-off should be immense. Features that 
are not signiﬁ  cant under the parametric, distribution-
dependent tests can become signiﬁ  cant under the 
permutation test for signiﬁ  cance, and the reverse 
shifts are also possible. This becomes especially 
important when using signiﬁ  cance levels to select 
n-ranked features. When permutation feature selec-
tion methods are then combined with classiﬁ  cation 
algorithms such as PCA, SVM, or nearest neighbor 
algorithms, and then are evaluated by PACE or 
bootstrap methods, this clearly will require a large 
network dedicated to cancer proteomic analysis, 
and a consortium of developers dedicated to bring-
ing well-known existing and new algorithms for 
analysis to bear on the important problems in can-
cer research, including early detection, recurrence, 
progression and therapy outcome. A plan to use 
the rational uniﬁ  ed process outlined in caCORE 
(Covitz et al., 2003) as a software development 
protocol will help combine the energies of par-
ticipants and developers in the Integrative Cancer 
Workspace of NCI’s caBIG workspace with those 
of participants in the EDRN is under development. 
We intend to build a parallel-processing friendly 
analysis framework so researchers can objectively 
evaluate and report the effects of the decisions they 
make during each stage in analysis. Even so, sup-
port of analysis for small (pilot) studies is needed, 
and we can reasonably expect that optimal analy-
sis solutions to vary with study design. The 
reanalysis of published data sets will also be key 
to sorting through the method space, so the design 
of such a solution might include data sets ‘on-tap’, 
as we have done for caGEDA (http://bioinformat-
ics.upmc.edu/GE2/GEDA.html) for microarray 
data analysis (Patel and LyonsWeiler, 2004). 
Simulations will also be key. We encourage sites 
to make their raw data (unpreprocessed) and source 
code available under an open source license to 
resolve analysis challenges as rapidly and as 
directly as possible.
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Figure A1: PACE analysis using a SVM-based classiﬁ  er using the AUC scoring criterion, with a 0.6 MAC threshold. Left Panel: performance 
without peak selection. Right panel: performance with peak selection. In these ﬁ  gures, the upper solid line represents the Mean Achieved 
Classiﬁ  cation Error (MACE) under the null hypothesis derived using sample class label permutations. The next two dotted lines represent 
the 95
th and 99
th percentile, and the lower solid line represents the ACE for the classiﬁ  er (averaged over iterations).
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Figure A2: PACE analysis using a SVM-based classiﬁ  er using the Fisher scoring criterion, with a 0.6 MAC threshold. Left Panel: performance 
without peak selection. Right panel: performance with peak selection.
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Figure A3: PACE analysis using a SVM-based classiﬁ  er using the J5 scoring criterion, with a 0.6 MAC threshold. Left Panel: performance 
without peak selection. Right panel: performance with peak selection.
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Appendix A: PACE examples for the UPCI pancreatic cancer dataset (Zeh 
et al., unpublished)71
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Figure A4: PACE analysis using a SVM-based classiﬁ  er using the simple separability scoring criterion, with a 0.6 MAC threshold. Left Panel: 
performance without peak selection. Right panel: performance with peak selection.
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Figure A5: PACE analysis using a SVM-based classiﬁ  er using the t-test scoring criterion, with a 0.6 MAC threshold. Left Panel: performance 
without peak selection. Right panel: performance with peak selection.
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Figure A6: PACE analysis using a SVM-based classiﬁ  er using the weighted separability scoring criterion, with a 0.6 MAC threshold. Left 
Panel: performance without peak selection. Right panel: performance with peak selection.72
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Figure B1: PACE analysis using a SVM-based classiﬁ  er using the AUC scoring criterion, with a 0.6 MAC threshold. Left Panel: performance 
without peak selection. Right panel: performance with peak selection.
Appendix B: PACE examples for the February ovarian cancer dataset (Petricoin 
et al., 2002)
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Figure B2: PACE analysis using a SVM-based classiﬁ  er using the Fisher scoring criterion, with a 0.6 MAC threshold. Left Panel: performance 
without peak selection. Right panel: performance with peak selection.
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Figure B3: PACE analysis using a SVM-based classiﬁ  er using the J5 scoring criterion, with a 0.6 MAC threshold. Left Panel: performance 
without peak selection. Right panel: performance with peak selection.73
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Figure B4: PACE analysis using a SVM-based classiﬁ  er using the simple separability scoring criterion, with a 0.6 MAC threshold. Left Panel: 
performance without peak selection. Right panel: performance with peak selection.
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Figure B5: PACE analysis using a SVM-based classiﬁ  er using the t-test scoring criterion, with a 0.6 MAC threshold. Left Panel: performance 
without peak selection. Right panel: performance with peak selection.
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Figure B6: PACE analysis using a SVM-based classiﬁ  er using the weighted separability scoring criterion, with a 0.6 MAC threshold. Left 
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Appendix C: PACE examples for the April ovarian cancer dataset (Petricoin 
et al., 2002)
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Figure C1: PACE analysis using a SVM-based classiﬁ  er using the AUC scoring criterion, with a 0.6 MAC threshold. Left Panel: performance 
without peak selection. Right panel: performance with peak selection.
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Figure C2: PACE analysis using a SVM-based classiﬁ  er using the Fisher scoring criterion, with a 0.6 MAC threshold. Left Panel: perform-
ance without peak selection. Right panel: performance with peak selection.
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Figure C3: PACE analysis using a SVM-based classiﬁ  er using the J5 scoring criterion, with a 0.6 MAC threshold. Left Panel: performance 
without peak selection. Right panel: performance with peak selection.75
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Figure C4: PACE analysis using a SVM-based classiﬁ  er using the simple separability scoring criterion, with a 0.6 MAC threshold. Left Panel: 
performance without peak selection. Right panel: performance with peak selection.
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Figure C5: PACE analysis using a SVM-based classiﬁ  er using the t-test scoring criterion, with a 0.6 MAC threshold. Left Panel: performance 
without peak selection. Right panel: performance with peak selection.
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Figure C6: PACE analysis using a SVM-based classiﬁ  er using the weighted separability scoring criterion, with a 0.6 MAC threshold. Left 
Panel: performance without peak selection. Right panel: performance with peak selection.76
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Appendix D: PACE examples for the prostate cancer dataset (Qu et al., 2002)
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Figure D1: PACE analysis using a SVM-based classiﬁ  er using the AUC scoring criterion, with a 0.6 MAC threshold. Left Panel: performance 
without peak selection. Right panel: performance with peak selection.
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Figure D2: PACE analysis using a SVM-based classiﬁ  er using the Fisher scoring criterion, with a 0.6 MAC threshold. Left Panel: performance 
without peak selection. Right panel: performance with peak selection.
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Figure D3: PACE analysis using a SVM-based classiﬁ  er using the J5 scoring criterion, with a 0.6 MAC threshold. Left Panel: performance 
without peak selection. Right panel: performance with peak selection.77
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Figure D4: PACE analysis using a SVM-based classiﬁ  er using the simple separability scoring criterion, with a 0.6 MAC threshold. Left Panel: 
performance without peak selection. Right panel: performance with peak selection.
+
+ + + + +
+
+ + + + +
x
x x x x x
x
x x x
x x
51 015 20 25
0
0
0.1
0.2
0.3
0.4
0.5
A
c
h
i
e
v
e
d
 
C
l
a
s
s
i
f
i
c
a
t
i
o
n
 
E
r
r
o
r
 
Feature Space Size 
MACE
ACE
95th %
99th %
5 10 15 20 25
0
0
0.1
0.2
0.3
0.4
0.5
MACE
ACE
95th %
99th %
A
c
h
i
e
v
e
d
 
C
l
a
s
s
i
f
i
c
a
t
i
o
n
 
E
r
r
o
r
 
Feature Space Size 
Figure D5: PACE analysis using a SVM-based classiﬁ  er using the t-test scoring criterion, with a 0.6 MAC threshold. Left Panel: performance 
without peak selection. Right panel: performance with peak selection.
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Figure D6: PACE analysis using a SVM-based classiﬁ  er using the weighted separability scoring criterion, with a 0.6 MAC threshold. Left 
Panel: performance without peak selection. Right panel: performance with peak selection.